No accomplices. Just a smart trader. Small biotechs in phase II/III should not have a mkt cap of over $500 milion. I have been reading Yahoo Message Board as an indication to buy or sell. Have you notice when the stock was $3 or under, "John" is just back from a miraculous infusion? Don't discount individuals that have been making a living trading for 20 years.
When I say everyone, I include myself. Results from Imbark is not yet available, so, we all speculate. That's not a winning formula for investing in tiny biotechs. I don't need to be first, I just need to make money. BTW, I have a portfolio the can choke a couple of hamsters.
One last titbit. You know that poster with her husband, John, is a complete lie. Everyone going under trials sign confidentiality agreements. And if it is truely saving her husband life why jeopardize it by divulging info.
The CEO has repeatedly stated the interest to purchase another compound. The value of that purchase is unknow. The sampling size from the Mayo Clinic isn't large enough. Maybe Imbark can confirm the results. But until that's know, $650 million mkt cap is too optimistic. I like what they are doing, but not the valuation. Spec Bio Tech in phase II/III should not have a mkt cap of $500. We are in a new enviroment, so trade accordingly. The chance of success is still less than 10%, I'm being generous.
Maybe even a little over valued given what is known. Was long at $3.10. Out at $4.01. I need concrete info regarding MF and MDS. Be careful people, extremely mature companies like GERN won't open up 100% or more. Too many trapped longs.